Abstract 38P
Background
Claudin 18.2 (CLDN18.2) is expressed in normal gastric tissue and gastric cancers. Zolbetuximab is a chimeric IgG1 monoclonal antibody that selectively targets CLDN18.2, inducing antibody- and complement-dependent cytotoxicity and cancer cell lysis. In phase 3 studies of zolbetuximab for HER2-negative, advanced gastric/gastroesophageal junction adenocarcinomas (SPOTLIGHT, GLOW), the most frequent adverse events were nausea and vomiting (N/V). We investigated the mechanism of zolbetuximab-induced N/V and effects of antiemetic agents on gastric injury and emesis frequency in ferrets.
Methods
Ferrets were administered zolbetuximab with/without single or combination antiemetic treatment (Table). Retching/vomiting were monitored for 6 hours, after which gastric tissues were sampled for histopathologic assessment. The study was conducted twice. Table: 38P
Study groups
Antiemetic Agent(s) | |||
Group (n=4, each study) | Emesis Agent | Study 1 | Study 2 |
1 – Normal | Saline IV | --- | |
2 – Control | Zolbetuximab 1 mg/kg IV | --- | |
3 – DEX | DEX 20 mg/kg IV | ||
4 – OND | OND 3 mg/kg IV | ||
5 – FOS | FOS 3 mg/kg IV | ||
6 – OLA | OLA 0.03 mg/kg IM | ||
7 – Combination | DEX+OND+FOS+OLA | OND+FOS |
DEX, dexamethasone; FOS, fosaprepitant; IM, intramuscular; IV, intravenous; OLA, olanzapine; OND, ondansetron.
Results
Zolbetuximab induced emesis within 30 minutes of administration. Singly, dexamethasone (DEX), ondansetron (OND), and fosaprepitant (FOS) significantly reduced emesis vs control (no antiemetic) in Study 1; olanzapine (OLA) did not. In Study 2, FOS alone (but not DEX, OND, or OLA) almost completely suppressed emesis. Further, both combination regimens containing FOS reduced emesis. Histopathologic analysis indicated that zolbetuximab induced gastric injury, evidenced by submucosal inflammation in the corpus and pylorus. DEX alone and the DEX-based combination regimen showed a tendency to alleviate submucosal inflammation in the corpus and pylorus, although the other antiemetics did not show any clear suppression of gastric mucosal damage. The combination of OND+FOS also tended to alleviate gastric mucosal abnormalities.
Conclusions
These findings in ferrets demonstrate that zolbetuximab-induced emesis may be associated with gastric mucosal damage. Further, antiemetics may have the potential to mitigate N/V in patients treated with zolbetuximab.
Clinical trial identification
Editorial acknowledgement
This study is funded by Astellas Pharma, Inc. Medical writing/editorial support was provided by Sandra Westra, PharmD, Pamela Barendt, PhD, and Cheryl Casterline, MA, from Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by the study sponsor.
Legal entity responsible for the study
Astellas Pharma, Inc.
Funding
Astellas Pharma, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09